» Articles » PMID: 29195829

Importance of Vancomycin Loading Doses in Intermittent Infusion Regimens

Overview
Publisher Elsevier
Date 2017 Dec 3
PMID 29195829
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Delayed achievement of target vancomycin serum concentrations may adversely affect clinical outcomes. The objective of this retrospective study was to explore the real frequency of loading dose use and to evaluate the impact of loading dose for the achievement of vancomycin PK/PD target in adult patients treated with intermittent vancomycin. As a secondary aim we determined optimal vancomycin loading dose based on individual pharmacokinetic calculations.

Methods: Vancomycin pharmacokinetic models were computed using two-compartmental analysis. Based on these models AUC were calculated. Unpaired t-test was used to compare AUC achieved in patients treated with and without vancomycin loading dose.

Results: Vancomycin loading dose was administered only in 17.8% patients. Volume of distribution and clearance median values (interquartile range) for vancomycin in whole study population (n = 45) were 0.69 (0.55-0.87) L/kg and 0.0304 (0.0217-0.0501) L/h/kg, respectively. The AUC was significantly higher in patients taking loading dose compared with the group without loading dose: mean (SD) AUC was 496 (101) vs. 341 (77) mg h/L. Proportion of patients reaching PK/PD goal was 87.5% and 24.3% with and without loading dose administration, respectively. Considering individual pharmacokinetic parameters optimal vancomycin loading dose was 27.5 mg/kg of body weight.

Conclusions: Loading dose administration plays crucial part in rapid attainment of vancomycin PK/PD target in adult patient treated with intermittent vancomycin, although it is not frequently used in clinical practise. The optimal loading dose of 25-30 mg/kg of body weight should be routinely administered to adult patients treated with intermittent vancomycin.

Citing Articles

The Impact of Augmented Renal Clearance on Vancomycin Pharmacokinetics and Pharmacodynamics in Critically Ill Patients.

Tesfamariam N, Aboelezz A, Mahmoud S J Clin Med. 2024; 13(8).

PMID: 38673590 PMC: 11051385. DOI: 10.3390/jcm13082317.


Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Matsumoto K, Oda K, Shoji K, Hanai Y, Takahashi Y, Fujii S Pharmaceutics. 2022; 14(3).

PMID: 35335866 PMC: 8955715. DOI: 10.3390/pharmaceutics14030489.


Initial dosing of intermittent vancomycin in adults: estimation of dosing interval in relation to dose and renal function.

Sima M, Hartinger J, Grus T, Slanar O Eur J Hosp Pharm. 2021; 28(5):276-279.

PMID: 34426481 PMC: 8403779. DOI: 10.1136/ejhpharm-2019-002013.


Impact of a vancomycin loading dose on the achievement of target vancomycin exposure in the first 24 h and on the accompanying risk of nephrotoxicity in critically ill patients.

Hodiamont C, Juffermans N, Berends S, van Vessem D, Hakkens N, Mathot R J Antimicrob Chemother. 2021; 76(11):2941-2949.

PMID: 34337660 PMC: 8521408. DOI: 10.1093/jac/dkab278.


The antibiotic vancomycin induces complexation and aggregation of gastrointestinal and submaxillary mucins.

Dinu V, Lu Y, Weston N, Lithgo R, Coupe H, Channell G Sci Rep. 2020; 10(1):960.

PMID: 31969624 PMC: 6976686. DOI: 10.1038/s41598-020-57776-3.